Martin Kolb,1 Kevin R Flaherty,2 Rafael S Silva,3 Antje Prasse,4 Nina M Patel,5 Carlo Vancheri,6 Manuel Quaresma,7 Rainer-Georg Goeldner,8 Susanne Stowasser,7 Rozsa Schlenker-Herceg,9 Athol U Wells10 on behalf of the INBUILD trial investigators
1McMaster University and St. Joseph’s Healthcare, Hamilton, Ontario, Canada; 2University of Michigan, Ann Arbor, MI, USA; 3Centro de Investigación del Maule, Talca, Chile; 4MHH Hannover Medical School, Department of Respiratory Medicine, Hannover, Germany; 5Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons/ New York-Presbyterian Hospital, New York, NY, USA; 6Regional Referral Center for Rare Lung Diseases, University-Hospital “Policlinico G. Rodolico”; 7Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 8Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; 9Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 10National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute, Imperial College, London, UK
Introduction
- In the INBUILD trial in patients with chronic fibrosing ILDs with a progressive phenotype (other than idiopathic pulmonary fibrosis [IPF]), nintedanib slowed the rate of decline in forced vital capacity (FVC) (mL/year) versus placebo, with adverse events that were manageable for most patients.1